Patient Engagement: How Soon Do You Start?
Executive Summary
Julie Adrian, European managing director of inVentiv Health Communications, outlines the greatest barriers preventing companies from engaging patients earlier in drug development and highlights the greatest benefits on offer to those that can successfully implement patient-centric drug discovery models.
You may also be interested in...
Rise of the patient affairs officer; Sanofi makes appointment
Following the growing trend of pharmaceutical companies embracing patient-centric business models, Sanofi has appointed Dr Anne C Beal chief of patient affairs. The French pharma is the first of the top ten biopharmaceutical companies to create space for such a position, according to Pascale Witz executive vice-president of global and strategic development.
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.
Podcast: NodThera On The Role Of The Brain In Driving Chronic Disease
Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity.